- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07382739
Un estudio de fase 2 de la inmunopreparación inducida por radioterapia para potenciar el elranatamab (Elra) en el mieloma múltiple recidivante refractario (RRMM) con enfermedad extramedular (EMD) y enfermedad paramedular (PMD) "PRIME-EMD-PMD"
Un estudio de fase 2 de preparación inmunitaria inducida por radioterapia para potenciar el elranatamab (Elra) en mieloma múltiple recidivante refractario (RRMM) con enfermedad extramedular (EMD) y enfermedad paramedular (PMD) "PRIME-EMD-PMD"
To learn if low doses of radiation therapy can help the drug elranatamab enhance the killing effect of the cancer cells.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Primary Objectives To evaluate the efficacy of RT-induced immune priming to enhance Elranatamab (Elra) in RRMM with EMD or PMD as measured by overall response rate (ORR) at 3 months
Secondary Objectives To describe adverse events (AEs). To determine time to next treatment (TTNT). To evaluate progression-free survival (PFS). To determine overall survival (OS). To estimate quality of life (QOL). To assess local control to the irradiated lesions To determine differences in response in patients with EMD vs PMD To determine differences in response in patients High Risk (HR) vs Standard Risk (SR) disease
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Christine Ye, MD
- Número de teléfono: 832-748-6369
- Correo electrónico: jcye@mdanderson.org
Ubicaciones de estudio
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- Reclutamiento
- MD Anderson Cancer Center
-
Investigador principal:
- Christine Ye, MD
-
Contacto:
- Christine Ye, MD
- Número de teléfono: 832-748-6369
- Correo electrónico: jcye@mdanderson.org
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Niño
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria
-
RRMM exposed to IMID, PI, anti-CD38 mAb, relapsed or refractory to at least one prior line of therapy (LOT), progressed on or after the last regimen:
- Relapsed disease: progressive disease (PD) >60 days after cessation of prior therapy
- Refractory disease: PD <=60 days after cessation of prior therapy, <25% reduction in paraprotein (monoclonal protein [M-protein] or serum free light chains [sFLC]) or measurements of EMD/PMD
-
Diagnosis of relapsed or refractory multiple myeloma as indicated by progression by IMWG criteria
-
At least one locus of EMD or PMD present on imaging (either PET/CT or magnetic resonance imaging [MRI]):
-
EMD: extramedullary plasmacytoma, not a contiguous extension from a bone lesion.
-
PMD: paraskeletal plasmacytoma, contiguous extension from a bone lesion At least one locus of EMD/PMD that was not previously radiated and can be treated with radiation
-
Hematology (supportive care is allowed, including transfusions and granulocyte colony stimulating factor (G-CSF), if cytopenia is deemed secondary to myeloma disease burden):
-
Hemoglobin (Hgb) >=7g/dL
-
Platelet>=50K/uL
-
Absolute neutrophil count (ANC) >=0.75K/uL
-
Chemistry:
-
Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) <=2.5 x upper
-
limit of normal (ULN)
-
Total bilirubin (TBili) <=1.5ULN (except for a known history of Gilbert syndrome)
-
Creatinine clearance (CrCL) >=30mL/min/1.73m2
-
Eastern Cooperative Oncology Group Performance Status (ECOG PS) <=2, unless ECOG PS due to pain/morbidity secondary to underlying myeloma disease, with the potential of improved ECOG PS to <=2.
-
All participants must be either
-
Not of childbearing potential, or
-
Practicing at least 1 highly effective method of contraception until 6 months after the last dose of study treatment.
-
Childbearing age female participantsmust have a negative serum pregnancy test at screening and must agree to further pregnancy tests during the study.
Exclusion Criteria
-
Prior or concurrent exposure to any of the following in the specified time frame prior to the first dose of Elra treatment:
- Within 14 days or at least 5 half-lives, whichever is less, of any investigational treatment
- Within 7 days of IMIDs, PI, anti-CD38 mAb, or cytotoxic systemic myeloma therapies
- Within 12 weeks of autologous stem-cell therapy (ASCT) or 6 months of AlloSCT and has to be off immunosuppressive agents >=42 days without signs of graft versus host disease (GVHD)
- Within 2 weeks of major surgery
- Within 6 months of cerebrovascular accident (CVA) events
-
Waldenstrom, POEMS, Amyloidosis, ongoing plasma cell leukemia (PCL)
-
History of Human Immunodeficiency Virus (HIV)
-
Active, uncontrolled HBV infection despite antiviral therapy.
-
Uncontrolled cardiac, pulmonary, gastrointestinal (GI), hepatic, renal, central nervous system(CNS) diseases not due to myeloma, at the discretion of investigator, that are not a candidate for T cell engager (TCE) therapy
-
Uncontrolled or recurrent infections
-
Autoimmune disease requiring systemic treatment (except for low dose steroids, equivalent to 10mg/day or less of prednisone)
-
Disabling psychiatric conditions, substance abuse (alcohol, or drug), dementia, altered mental status
-
Any other active malignancies within 5 years of completing treatment (with the exception of hormonal therapies for breast or prostate cancer) and >minimal risk of recurrence
-
Myelodysplastic syndromes (MDS)
-
Any issues that may impair the ability of the participant to receive or tolerate the planned treatment, to understand the informed consent, or any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant or that would prevent, limit, or confound the protocol specified assessments.
-
History of allergic reactions attributed to compounds of similar chemical or biologic composition to Elra or other agents used in study.
-
History or possible non-compliance with recommended treatments
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Treatment with Elranatamab (SubQ) Q4W
To evaluate the efficacy of RT-induced immune priming to enhance Elranatamab (Elra) in RRMM with EMD or PMD as measured by overall response rate |
Given by IV |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Safety and adverse events (AEs)
Periodo de tiempo: Through study completion; an average of 1 year
|
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0 |
Through study completion; an average of 1 year
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Christine Ye, MD, M.D. Anderson Cancer Center
Publicaciones y enlaces útiles
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades Vasculares
- Enfermedades cardiovasculares
- Neoplasias
- Enfermedades del sistema inmunológico
- Neoplasias por tipo histológico
- Enfermedades hematológicas
- Trastornos linfoproliferativos
- Trastornos inmunoproliferativos
- Neoplasias De Células Plasmáticas
- Trastornos hemostáticos
- Paraproteinemias
- Trastornos de proteínas en sangre
- Trastornos hemorrágicos
- Enfermedades hemic y linfáticas
- Mieloma múltiple
Otros números de identificación del estudio
- 2025-1557
- NCI-2026-00668 (Otro identificador: NCI-CTRP Clinical Registry)
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .